Psychiatry and Neurology, Neurology · Hickory, NC
NPI
1629031323
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1985 Tate Blvd SE, Suite 600
Hickory, NC, 28602
Phone (828) 485-2510
Groups this clinician bills Medicare through
Medicare paid, 2024
$96K
2,793 services
Medicare patients, 2024
569
Average age 73
Drug cost, 2024
$2.8M
6,664 prescriptions
Company payments, 2025
$1,911
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dale A Menard Jr. was code 99214 (office e&m - established), 391 times for 262 patients. In total Dale A Menard Jr. billed 2,793 services in 29 codes, and Medicare paid $96K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 391 | 262 | $78.75 | $31K |
| 95886 Electrical Nerve Conductivity | Office | 131 | 129 | $67.91 | $8,896 |
| 95910 Electrical Nerve Conductivity | Office | 75 | 75 | $119.20 | $8,940 |
| 95912 Electrical Nerve Conductivity | Office | 71 | 71 | $170.31 | $12K |
| 95885 Electrical Nerve Conductivity | Office | 56 | 53 | $43.73 | $2,449 |
| 99222 Hospital E&M - Initial | Facility | 36 | 35 | $92.65 | $3,335 |
| 99232 Hospital E&M - Subsequent | Facility | 35 | 22 | $57.07 | $1,998 |
| 95909 Electrical Nerve Conductivity | Office | 20 | 20 | $93.82 | $1,876 |
| 99204 Office E&M - New | Office | 19 | 19 | $120.48 | $2,289 |
| 95811 Sleep Study | Facility | 19 | 17 | $86.60 | $1,645 |
| 99223 Hospital E&M - Initial | Facility | 18 | 18 | $127.24 | $2,290 |
| 95816 Neurologic | Facility | 17 | 16 | $39.62 | $674 |
| 95810 Sleep Study | Facility | 17 | 17 | $71.66 | $1,218 |
By year: 2022 $147K for 3,868 services; 2023 $120K for 2,984 services; 2024 $96K for 2,793 services.
Medicare prescription drug claims, 2024
In 2024, the drug Dale A Menard Jr. prescribed most often to Medicare patients was Clonazepam, with 465 prescriptions and refills. In total Dale A Menard Jr. wrote 6,664 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clonazepam Generic | 465 | 628 | 84 | $4,580 |
| Topiramate Generic | 431 | 975 | 99 | $4,993 |
| Gabapentin Generic | 368 | 820 | 112 | $10K |
| Memantine Hcl Generic | 342 | 729 | 87 | $9,260 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 262 | 646 | 65 | $7,091 |
| Donepezil Hcl Generic | 242 | 576 | 71 | $2,443 |
| Quetiapine Fumarate Generic | 225 | 476 | 67 | $3,290 |
| Duloxetine Hcl Generic | 209 | 444 | 55 | $4,816 |
| Sumatriptan Succinate Generic | 193 | 226 | 26 | $13K |
| Aimovig Autoinjector Erenumab-Aooe | 168 | 241 | 29 | $178K |
| Levetiracetam Generic | 166 | 398 | 43 | $5,388 |
| Mirtazapine Generic | 162 | 334 | 50 | $1,956 |
| Escitalopram Oxalate Generic | 151 | 298 | 41 | $1,364 |
| Pregabalin Generic | 143 | 275 | 36 | $5,544 |
| Lamotrigine Generic | 115 | 279 | 30 | $2,034 |
Brand drugs: 852 claims; generic drugs: 5,797 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dale A Menard Jr. $1,911 ($1,911 in general payments such as food, travel and fees) from 26 companies. The largest payer was Teva Pharmaceuticals USA, Inc. with $558.
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. TEVA | 32 | $558 |
| Abbvie Inc. ABBV | 43 | $342 |
| Pfizer Inc. PFE | 16 | $177 |
| Axsome Therapeutics, Inc. AXSM | 3 | $93.33 |
| Aucta Pharmaceuticals, Inc. | 4 | $81.08 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $61.76 |
| EMD Serono, Inc. MRK.DE | 2 | $57.09 |
| CSL Behring CSL.AX | 2 | $54.49 |
| Genentech USA, Inc. ROG.SW | 2 | $51.62 |
| ACADIA Pharmaceuticals Inc ACAD | 2 | $49.95 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.